IL17A and psoriasis: Regarding the effects of IL-27 on the pathogenesis of psoriasis, Shibata et al. reported that IL-27 activated Th1-mediated responses to exacerbate IMQ-induced psoriasis-like skin lesions without affecting IL-17 [37], while Chen et al. found that subcutaneous administration of IL-27 recombinant protein lessened severity of IMQ-induced psoriasis-like cutaneous lesions by suppressing the production of IL-17 [35].